The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti‐ PD ‐1 antibody and paclitaxel
Cancer Science · 2024
DOI: 10.1111/cas.16366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Chiaki Kobayashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kyowa Kirin Co., Ltd., Shizuoka, Japan. Hauptthemen laut MEDLINE: Paclitaxel, CD40 Antigens, Macaca fascicularis, Mice, Transgenic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Lack of tumor‐reactive cytotoxic T lymphocytes (CTLs) limits the antitumor efficacy of immune checkpoint inhibitors (ICIs). CD40 agonists have been expected to overcome this limitation by generating tumor‐reactive CTLs. However, the clinical efficacy of CD40 agonistic antibodies is not as good as in non‐clinical studies. The novel human CD40 (hCD40) agonist KHK2840 is a fully human anti‐CD40 IgG2 agonistic antibody that is Fc‐engineered to minimize complement‐dependent cytotoxicity and antibody‐dependent cellular cytotoxicity. Compared to other hCD40 agonists, KHK2840 exhibited the most potent hCD40 agonistic signal in tumor‐bearing hCD40 transgenic mice and human peripheral blood B cells. Moreover, KHK2840 enhanced the antitumor efficacy of the antiprogrammed cell death 1 antibody and paclitaxel. Comprehensive immune profiling revealed that the antitumor immune response of the triple combination involved tumor‐draining lymph nodes in addition to tumor microenvironments. This suggests that a coordinated antitumor immune response between tumors and lymph nodes may underlie the synergistic antitumor efficacy of the triple combination therapy. Finally, a toxicology study in cynomolgus monkeys demonstrated that KHK2840 activated the CD40 signal with tolerable toxicological properties. These results indicate that KHK2840 is a novel and potent hCD40 agonistic antibody for cancer immunotherapy, which is expected to augment the antitumor efficacy of ICIs and chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kyowa Kirin Co., Ltd., Shizuoka, Japan.
ORCID-Profile: Chiaki Kobayashi, Masato Saito
Zitieren
APA
Kobayashi, C., Suzuki-Imaizumi, M., Sakaguchi, Y., Ishii, T., Adachi, M., Kaneda, A., Ebihara, R., Saito, M., Uemori, T., & Mori, K. (2024). The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti‐ PD ‐1 antibody and paclitaxel. Cancer Science. https://doi.org/10.1111/cas.16366
Vancouver
Kobayashi C, Suzuki-Imaizumi M, Sakaguchi Y, Ishii T, Adachi M, Kaneda A, et al. The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti‐ PD ‐1 antibody and paclitaxel. Cancer Science. 2024. doi:10.1111/cas.16366
BibTeX
@article{Kobayashi2024,
author = {Kobayashi, Chiaki and Suzuki-Imaizumi, Minami and Sakaguchi, Yasuko and Ishii, Toshihiko and Adachi, Maiko and Kaneda, Ayumi and Ebihara, Ritsuko and Saito, Masato and Uemori, Takeshi and Mori, Kiyotoshi},
title = {The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti‐ PD ‐1 antibody and paclitaxel},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16366}
}
EUVIMED